This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.

You’re back. We’re sort of back. It’s Day 2 of JPM and we’re definitely not exhausted or delirious yet.

This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We’ve got a lot more news today, so let’s get to it.

The next test for Kite Pharma — and Gilead

It’s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.

Continue to STAT+ to read the full story…

A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that’s captured the attention of pharmaceutical executives and investors worldwide. 

On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China Pharmaceutical Innovation and Invention Index. The report joins a global pharmaceutical ranking that IDEA produces every spring. 

The rankings were chosen from a list of 50 companies around China. The report ranks the top companies for invention — namely, which companies are developing new medicines that matter and use novel science — and innovation, which assesses how these companies are developing and launching medicines. Research spending, international patent filings, and drug approvals all factor into a company’s standing. 

Continue to STAT+ to read the full story…